الفهرس 
COVID-19Only 14 pages are availabe for public view
 |  | from | 136 |  |  |
| | | from | 136 | | |
Abstract
S
ince coronavirus disease 2019 (COVID-19) became a global pandemic, concerns have arisen that immunocompromised patients may be at greater risk of severe infection.
Viral culture remains the gold standard for definitively measuring viral viability; however, given the technical demands of viral culture, including the requirement for biosafety level 3 facilities, other diagnostic approaches such as nasopharyngeal (NP) PCR have emerged to estimate viral loads.
Childhood cancer is a highly curable disease when timely, accurate diagnosis and appropriate therapy are provided. Children with cancer are particularly at risk of suffering the consequences of resource reallocations by having lifesaving treatments delayed, interrupted, or significantly modified. Scattered reports describe the clinical manifestations and outcomes of COVID-19 in children, including in a few patients with cancer who were receiving treatment.
The study aimed to Measure the frequency of COVID-19 infection among children with hemato-oncological disorder in a period from 1st December 2019 till 30th November 2021 and to develop a registry dataset which can be used as a template for national registry for children with hemato-oncological disorder with proven COVID19 infection.
This is retrospective cohort non-intervention study that included 620 patients with malignancy either hematological or solid tumors. The study was conducted at Ain Shams University Hospital, Cairo, Egypt, in accordance with the ethical standards stated by the Ethical Committee of Ain Shams University
All data were collected from medical records including history, clinical symptoms and laboratory investigation (Complete blood count, COVID-19 RT-PCR, C-reactive proteinو serum ferritin level, Coagulation tests, cardiac enzymes if needed and routine bacteriological study and blood culture) and imaging (Chest X-ray and CT chest).
Our study showed that the percentage of patients with hematological malignancy and ALL, specially patients with acute precursor B lymphoblastic leukemia was found significantly higher in patients with COVID-19 than those without COVID-19. While the percentage of patients with benign hematology was found significantly higher in patients without COVID-19 than patients with COVID-19
We found that there was significant difference found between survived and died patients regarding ordinal score for respiratory support and percentage of patients admitted to ICU.
CONCLUSION
I
n our current study showed that the percentage of patients with COVID-19 were higher among patients with hematological malignancies and benign hematological diseases, especially acute lymphoblastic leukemia and aplastic anemia respectively. COVID-19 was tolerable among immunocompromised patients. Mortality was associated with abnormal neurological examination in patients with COVID-19 disease. Further studies with larger scales are needed to confirm our results